McCann, Kelly E.
Hurvitz, Sara A.
McAndrew, Nicholas
Article History
First Online: 28 June 2019
Compliance with Ethical Standards
:
: No external funding was used in the preparation of this manuscript.
: Kelly McCann serves on a speaker’s bureau for Eli Lilly’s CDK 4/6 inhibitor abemaciclib in patients with metastatic, hormone receptor-positive breast cancer. Sara Hurvitz reports receiving research grants from Ambryx, Amgen, Bayer, Obi Pharma, Biomarin, Cascadian, Daiichi Sankyo, Dignitana, Genentech, GSK, Lilly, Magrogenics, Medivation, Merrimack, Novartis, Pfizer, Pieris, Puma, Roche, Seattle Genetics, and travel support from Lilly, Novartis, and Obi Pharma. Nicholas McAndrew reports receiving research funding to his institution from Novartis and Daiichi Sankyo, research-related travel accommodations from Roche and Daiichi Sankyo, and an honorarium for a continuing medical education lecture from Med Learning Group/Ultimate Medical Academy, which was funded by an unrestricted education grant provided by Eli Lilly.